Baxter launches HEMOPATCH in European Union

Baxter announced the launch of HEMOPATCH Sealing Hemostat, following CE mark approval in Europe. HEMOPATCH is a resorbable hemostatic device used for surgical procedures when control of bleeding by pressure, ligature or conventional procedures is either ineffective or impractical. The development of HEMOPATCH combined Baxter’s expertise in collagen, internal coagulation processes, and PEG technology platforms. In preclinical tests, HEMOPATCH achieved fast and effective hemostasis, reaching 97.5% success by fully controlling bleeding at two minutes.

View Comments (0)